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Introduction 
Most cases of Graves’ orbitopathy (GO) are benign and require no special treatment. In the 
active moderate-to-severe lesion, constituting 5–6% of cases, according to EUGOGO 
guidelines, an intravenous course of corticosteroids is the first-choice treatment, effective in 
about 70–80% of cases. The management of patients who are refractory to corticosteroid 
therapy is a major challenge and includes repeated courses of corticosteroids, orbital 
radiotherapy, cyclosporin A, and rituximab [1]. CD4+ cell infiltrates in orbital tissues play a 
central role in the molecular pathways leading to proliferation and differentiation of orbital 
fibroblast and the secretion of hyaluronic acid and the adipogenesis. GO patients are 
characterised by a low number of circulating Treg cells among peripheral blood mononuclear 
cells (PBMCs) with high CD4/CD8 ratios and abnormal cytokine expression [2]. In vitro, 
incubation of PBMCs obtained in GO patients with rabbit anti-thymocyte globulin (rATG) for 
24 h substantially enhanced the expression of Treg cell markers FoxP3 and CD3+ CD4+ CD25+ 
CD127low [2]. 
Thymoglobulin (rATG) is a polyclonal rabbit antibody that causes T-cell depletion, used in the 
induction after kidney transplantation (KTx) and treatment of acute rejection. In addition, it was 
shown that ATG in vitro can induce apoptosis of naive plasma B cells and plasma cells [3], 
inhibit the secondary immune response by memory B cells via T-cell modulation, and induce 
regulatory T cells during immune reconstitution [4]; thereby, it may suppress B cells and 
production of antibodies. 
 
Case description 
A 47-year-old woman with a 25-year history of Graves-Basedow disease, after subtotal 
strumectomy, two courses of radioiodine therapy, on thyroxine substitution, developed bilateral 
GO (conjunctival oedema, double vision, worsening of visual acuity). During glucocorticoid 
therapy (after 3–4 courses) according to the EUGOGO protocol, the patient developed 
symptomatic optic neuropathy treated with radiotherapy (20 Gy in 10 fractions) with 
continuation of methylprednisolone to a total dose 11 g with subsequent ineffective 14-week 
therapy with cyclosporin A. In July 2018, after obtaining acceptance of the therapy with rATG 
by the Bioethics Committee, we offered an experimental therapy with thymoglobulin (two 
doses of 1.5 mg/kg) with pretreatment with methylprednisolone 250 and 125 mg, paracetamol, 
and clemastine. 
The clinical improvement in GO where noted at six-week examination and was maintained a 
year after rATG administration (Tab. 1). There was a significant improvement in the patients' 
clinical status, both subjective (GO-QOL EUGOGO questionnaire) and in the ophthalmologic 
tests: decrease in CAS from 5/7 to 0/7, subsiding of diplopia, improvement of best-corrected 
distance visual acuity - BCDVA (from 0.5 to 0.7 right eye — RE and from 0.5 to 0.9 left eye 
— LE), and colour vision recovery assessed with Ishihara colour plates (from 11/16 to 16/16 
RE and 10/16 to 16/16 LE). Improvement was noted in the NOSPECS scale (from 2-b, 4-c, 6-
a to 2-0, 4-b, 6-0), Donaldson’s ophthalmopathy index (from 6/15 to 3/15), and Octopus 1-2-3 
static perimetry (Haag Streit, Switzerland), with complete reduction of absolute scotomata and 
decrease in relative scotomata (Fig. 1) and VEP Pattern, both in latency, which decreased (P100 
latency after stimulation with 1° normalized and were delayed to 105% after stimulation with 
15′), and amplitude, which increased (Tab. 1). In addition, there was only a transient decrease 
in TRAb titre and persistent improvement in CD4/CD8 ratio of peripheral blood T lymphocytes. 
 
Discussion 
The presented case shows that patients with steroid-resistant GO may benefit from rATG 
therapy and that the obtained clinical remission is related to the long-lasting change in CD4 to 
CD8 ratio of peripheral blood T lymphocytes without disappearance of TRAb production. Our 
finding is not in line with the unique observation of the resolution of GO shortly after induction 
therapy with rATG (1.5 mg/kg/dose for five doses) with a triple immunosuppressive regimen 
(including glucocorticoids) in a kidney transplant recipient previously untreated for GO. The 
clinical improvement, in this case, was followed by the disappearance of TRAb after the 
procedure [5]. It should be stressed that in our patient glucocorticoid therapy, as well as RTH, 
were ineffective, and the available therapeutic options were exhausted.  
Severe dysthyroid optic neuropathy (DON) in the course of GO is a sight-threatening 
complication [6]. In some individuals tension and lack of laxity of orbital septum prevent the 
eye globe from self-decompressing, resulting in severe DON, regardless of slight or no 
exophthalmos. This situation was present in our patient, whose colour vision loss and visual 
field loss were severely affected by compression neuropathy. A year after the rATG 
administration we observed significant improvement in functional visual tests, which can be 
explained by optic nerve decompression. 
Therefore, we think that therapy with Thymoglobulin may be useful in the management of 
severe steroid-resistant GO. The effectiveness of this new therapy requires a larger number of 
observations. 
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Table 1. Evolution of clinical findings during a year after thymoglobulin administration in a 
patient with Graves’ ophthalmopathy 
 Before rATG 12 weeks 24 weeks One year 
Clinical  
symptoms 
Diplopia in every 
direction, abnormal 
acuity and colour 
vision 
Without diplopia, 
significant 
improvement of 
visual acuity and 
colour vision 
Slight diplopia 
when looking to the 
left, improvement 
of visual acuity and 
colour vision 
Periodic slight 
diplopia in every 
direction 
TSH [mU/L] 2.8 0.5 4.2 1.4 
TRAb [IU/L] > 40 > 40 > 40 > 40 
CD4/CD8 ratio 3.0 1.5 1.6              1.8 
DBCVA RE 0.5  
LE 0.5 
RE 0.8  
LE 0.9 
RE 0.8  
LE 1.0 
RE 0.7  
LE 0.9 
Exophthalmometry 
(Hertl) 
RE 16 mm 
LE 18 mm 
RE 16 mm 
LE 18 mm 
RE 16 mm 
LE 18 mm 
RE 16 mm 
LE 18 mm 
Donaldson 6/15 1/15 2/15 3/15 
CAS 5/7 1/7 0/7 1/7 
NOSPECS 2-b, 3-0, 4-c, 5-0, 6-
a 
2-a, 3-0, 4-0, 5-0, 6-
0 
2-0, 3-0, 4-b, 5-0, 6-
0 
2-a, 3-0, 4-b, 5-0, 6-
0 
Ishihara Colour 
Plates 
RE 11/16 
LE 10/16 
RE 15/16 
LE 15/16 
RE 16/16 
LE 16/16 
RE 16/16 
LE 16/16 
Static Visual Field 
MS (dB) 
MD (dB) 
 
RE      LE 
17.3  12.6 
10.7  15.4 
 
RE       LE 
25.4   22.3 
2.4       5.5 
RE       LE 
20.6   23.4 
7.3       4.4 
RE      LE 
26.4  25.4 
1.5      2.4  
PVEP  
1° 
P100 
N75-P100 
 
15′ 
P100 
N75-P100 
 
RE        LE 
 
116      118 
6.3       8.3 
 
 
136      128 
 6.9      4.8 
  RE       LE 
 
110      109 
9.0       8.9 
 
 
130      130 
9.9       10.1 
 
Orbital MR Active thyroid 
orbitopathy. 
Swelling of the 
extraocular 
muscles 
– Discrete reduction 
of extraocular 
muscle thickness 
by 1–2 mm 
Image comparable 
with the previous 
study 
CAS — Clinical Activity Scale; DBCVA — distance best corrected visual acuity, LE — left 
eye; MD — mean defect; MS — mean sensitivity; PVEP — pattern visual evoked potentials; 
RE — right eye  
Classification of Graves’ ophthalmopathy (NOSPECS): 0 — no signs or symptoms; 1 — only 
signs, no symptoms; 2 — soft-tissue involvement; 3 — proptosis; 4 — extraocular muscle 
involvement; 5 — corneal involvement; 6 — sight loss 
 
Figure 1. Octopus static visual field of the right (RE) and left (LE) eyes before rATG 
administration and after the one-year follow-up period 
  
